Home » Peregrine and Stason Agree on Innovative Tumor Necrosis Therapy Technologies
Peregrine and Stason Agree on Innovative Tumor Necrosis Therapy Technologies
Peregrine Pharmaceuticals … and Stason Pharmaceuticals, a privately-held U.S.-based pharmaceutical company commercializing products globally since
1994, Monday announced agreements granting Stason certain exclusive development and commercialization rights to Peregrine’s tumor necrosis therapy
technologies.
MarketWatch
MarketWatch
Upcoming Events
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May